• Home
    • StockRanks™
    • Platform
        • Research & Discuss
        • Editorial & Community
        • Learn & Improve
        • Webinars & Masterclasses
        • Stockopedia Academy
    • Reviews
    • Pricing
    Get startedLog in
    SectorsHealthcareHealthcare Equipment & SuppliesRenovoRx
    Picture of RenovoRx logo

    RNXT — RenovoRx News Story

    $0.920.000.00%
    us flag iconLast trade - 00:00
    HealthcareMicro CapSucker Stock
    • Market Cap
      $41.45m
    • Enterprise Value
      $29.09m
    • Revenue
      $1.12m
    • Quality
    • Value
    • Momentum
    • StockRank™
    • StockReport™
    • Accounts
      • Balance sheet
      • Income statement
      • Cashflow statement
      • Dividend summary
    • News
    • RNXT Dividends
    StockReport™
    Balance sheet
    Income statement
    Cashflow
    News
    RNXT Dividends
    All News

    Brief: RenovoRx Q1 Net Income USD -2.4 Million

    Picture of RenovoRx logoRenovoRx
    15/05/2025 21:05
    May 15 (Reuters) - RenovoRx Q1 operating income USD 800 thousand.
    

    Recent news on RenovoRx

    See all news
    • Brief: RenovoRx Gets FDA Orphan Drug Designation For Oxaliplatin To Treat Pancreatic Cancer

      28/05/2026 13:48
    • RenovoRx Q1 revenue rises as number of active cancer centers increase

      14/05/2026 21:20
    • RenovoRx 2025 net loss widens on higher operating expenses

      30/03/2026 21:25
    • Brief: RenovoRx FY Net Income USD -11.168 Million

      30/03/2026 21:05
    • U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies

      18/03/2026 17:49

    Company

    • About us
    • Careers
    • Product Guide

    Our Coverage

    • Countries
    • Sectors
    • Ratios

    Top Stocks

    • UK Stocks
    • Australian Stocks
    • US Stocks

    Legals

    • Privacy Policy
    • Terms & Conditions
    • Disclaimer & FSG
    • Cookies
    Trustpilot
    Select a country/region:


    © Stockopedia 2026, Refinitiv, Share Data Services.

    *Past performance is no indicator of future performance, and testimonials are provided by third parties for informational purposes only and are not intended and should not be taken to be financial product advice. Performance returns are based on hypothetical scenarios and do not represent an actual investment.

    This site cannot substitute for professional investment advice or independent factual verification. To use Stockopedia, you must accept our Terms of use, Privacy and Disclaimer & FSG. All services are provided by Stockopedia Ltd, United Kingdom (company number 06367267). For Australian users: Stockopedia Ltd, ABN 39 757 874 670 is a Corporate Authorised Representative of Daylight Financial Group Pty Ltd ABN 77 633 984 773, AFSL 521404.